Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.10.

A number of research analysts have weighed in on ELAN shares. The Goldman Sachs Group lifted their target price on Elanco Animal Health from $8.50 to $9.50 and gave the company a “sell” rating in a report on Tuesday, August 8th. Piper Sandler upped their target price on shares of Elanco Animal Health from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, August 14th.

Elanco Animal Health Trading Up 1.6 %

Shares of Elanco Animal Health stock opened at $12.39 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.53 and a current ratio of 2.84. The stock has a market capitalization of $6.10 billion, a P/E ratio of -61.95, a P/E/G ratio of 8.14 and a beta of 1.01. Elanco Animal Health has a 52-week low of $7.88 and a 52-week high of $16.14. The stock’s 50-day simple moving average is $11.38 and its 200 day simple moving average is $10.31.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Monday, August 7th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.13. Elanco Animal Health had a negative net margin of 2.24% and a positive return on equity of 6.93%. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the company posted $0.36 EPS. Elanco Animal Health’s revenue was down 10.2% compared to the same quarter last year. As a group, research analysts anticipate that Elanco Animal Health will post 0.85 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors have recently made changes to their positions in the stock. Glassman Wealth Services grew its position in Elanco Animal Health by 444.0% in the second quarter. Glassman Wealth Services now owns 2,644 shares of the company’s stock worth $27,000 after acquiring an additional 2,158 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Elanco Animal Health by 311.2% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,191 shares of the company’s stock valued at $30,000 after buying an additional 2,415 shares in the last quarter. Spire Wealth Management purchased a new position in shares of Elanco Animal Health during the 2nd quarter valued at about $30,000. Quadrant Capital Group LLC boosted its stake in Elanco Animal Health by 281.7% in the fourth quarter. Quadrant Capital Group LLC now owns 2,706 shares of the company’s stock worth $33,000 after buying an additional 1,997 shares in the last quarter. Finally, Ellevest Inc. boosted its stake in Elanco Animal Health by 38.0% in the first quarter. Ellevest Inc. now owns 4,406 shares of the company’s stock worth $41,000 after buying an additional 1,213 shares in the last quarter. Institutional investors own 95.29% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.